Patients with Advanced Pancreatic Cancer diagnosed by histopathology，the expected survival time is more than 3 months;
Neutropenia of ≥2 degree occurred with the nab-paclitaxel + S-1 regimen in the previous cycle.
KPS score≥70;
The peripheral blood routine of the patients was normal: ANC ≥ 2.0x10\^9/L, platelet count ≥ 90x10\^9/L, HB ≥ 80g/L before enrollment, and there was no bleeding tendency;
Patients volunteered to participate in the trial, signed a written informed consent, willing to be followed up.
You may not be if
There are uncontrollable infections at the moment or systemic antibiotic treatment within 72 h of chemotherapy；
Any abnormal bone marrow hyperplasia and other abnormal hematopoietic function；
Patients who had received bone marrow or hematopoietic stem cell transplantation within 3 months；
Patients with other malignancies that have not been cured or with brain metastases；
Total bilirubin(TBIL), alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \>2.5 ULN, or \>5 ULN if there is liver metastasis;
Serum creatinine (Cr) exceeded the upper limit of normal value；
Allergic to this product or other biological products derived from genetically engineered escherichia coli；
Suffering from a mental or nervous system disorder, without self-awareness or coordination；
Patients expected to have a short survival or have difficulty tolerating chemotherapy；
Pregnant or lactating female patients；
Patients using other drugs of the same category or in clinical trials of other drugs；
Not suitable for participation at investigators' discretion.
Clareo Health | PEG-rhG-CSF in Secondary Prevention of Nab-Paclitaxel Combined With S-1 in Advanced Pancreatic Cancer
